bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth

Benzinga03-13 22:30

bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619115310?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/13/Mystery-Rise-In-Otherwise-Healthy-Young-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-13 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619115310","market":"hk","top_or_hot":-1,"title":"bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth","media":"Benzinga","content":"<div>\n<p>bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nbioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4150","symbol_name":"赌场与赌博","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth","article_id":"2619115310","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/13/Mystery-Rise-In-Otherwise-Healthy-Young-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619115310","pubTimestamp":1773412200,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"bioAffinity Technologies shares are trading higher Friday after it reported FY25 results with strong growth in CyPath Lung diagnostic.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4150":"赌场与赌博","RSI":"Rush Street Interactive, Inc.","BIAF":"bioAffinity Technologies, Inc.","BK4139":"生物科技"},"translate_title":"bioAffinity Technologies股价因CyPath肺部销售额增长而飙升120%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIAF":1,"RSI":1},"content_text":"bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung diagnostic, even as total revenue declined following a strategic shift away from lower-margin lab services. Here’s what investors need to know.\nThe company said CyPath Lung revenue rose 87% year over year in 2025, while the number of tests performed jumped 99%. Orders from physician offices and clinics increased 67%, which bioAffinity attributed to stronger awareness, peer-to-peer physician marketing and positive real-world clinical experience with the test.\nNet loss widened to $14.9 million from $9.0 million a year earlier, driven in part by changes in the fair value of warrants, expanded sales activity and increased clinical development spending. Cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million, after the company raised about $16.9 million in 2025 financings.\nLooking ahead, bioAffinity said it expects CyPath Lung unit sales to increase more than 100% in 2026 as it expands commercialization and clinical validation efforts.\nThe Relative Strength Index (RSI) for bioAffinity Technologies fluctuated mostly within the neutral 30–70 range over the past year, with occasional dips into oversold territory and several brief spikes above the overbought threshold. \nOn Friday, the RSI surged above 70, signaling strong momentum and suggesting the stock may be entering overbought conditions after the latest rally.\nBIAF Price Action: bioAffinity Technologies shares were up 124.30% at $2.40 at the time of publication on Friday. The stock is near its 52-week low of $0.69, according to Benzinga Pro data.\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619115310","isCrawlerRequest":true}